Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06601998 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

Study acronym: HOMI-LUNG CAP
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 18 sitesv23
  2. Study sites: 17 to 18v22
  3. Site details revised at 1 of 17 sitesv21
  4. Study sites: 16 to 17v20
  5. Study completion date: Nov 8, 2027 to Jun 8, 2028
    • Site details revised at 1 of 16 sites
    v19
Show 17 earlier versionsHide 17 earlier versions
  1. Study sites: 15 to 16v18
  2. Site details revised at 1 of 15 sitesv17
  3. Study sites: 14 to 15v16
  4. Study sites: 13 to 14v15
  5. Site details revised at 1 of 13 sitesv14
  6. Study sites: 12 to 13v13
  7. Study sites: 11 to 12v12
  8. Site details revised at 1 of 11 sites
    • Eligibility criteria shortened, about 1 word
    v11
  9. Site details revised at 1 of 11 sitesv10
  10. Eligibility criteria expanded, about 6 words
    • Site details revised at 1 of 11 sites
    v9
  11. Study sites: 10 to 11v8
  12. Study sites: 9 to 10v7
  13. Site details revised at 1 of 9 sitesv6
  14. Study sites: 8 to 9v5
  15. Site details revised at 1 of 8 sitesv4
  16. Study sites: 7 to 8
    • Secondary endpoints: 15 to 14
    v3
  17. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 7
    • Primary and study completion dates: Oct 14, 2027 to Nov 8, 2027
    • Start date changed from estimate of Oct 14, 2024 to Nov 8, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies. The overall concept underpinning "Homi-lung" is to investigate the time course of host-microbiome interactions during \& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \& after pneumonia.
Trial Details
NCT Number NCT06601998
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions
(from sponsor)		 Pneumonia, Community-Acquired, COVID-19 Pneumonia, Cardiovascular Diseases
Related terms Cardiovascular Diseases, Community-Acquired Pneumonia, COVID-19, Respiration Disorders
Enrollment 650 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov